The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 2
Abstract
Portopulmonary hypertension (PPH) is an infrequent, but well-recognized complication of liver cirrhosis. PPH in those with end-stage liver disease has a significant impact on per-operative and intra-operative mortality, with liver transplantation being contraindicated in those individuals with mean pulmonary artery pressure exceeding 50 mmHg. Vasodilatory therapy is the mainstay of pharmacotherapy for PPH, although the evidence of benefit is largely extrapolated from the pulmonary hypertension literature. We report the use of the phosphodiesterase inhibitor, sildenafil, in a patient with end stage liver disease and PPH, with a pulmonary artery pressure before transplantation of 75 mmHg, to reduce pulmonary artery pressure prior to a successful liver transplant.
Authors and Affiliations
Ian Cadden, Erica Greanya, Siegfried Erb, Charles Scudamore, Eric Yoshida
Keywords
Related Articles
- EP ID EP77861
- DOI -
- Views 152
- Downloads 0
Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease
Background. This study aims to identify key genes and pathways involved in non-alcoholic fatty liver disease (NAFLD). Materialand methods. The dataset GSE48452 was downloaded from Gene Expression Omnibus, including 14 c...
IgG4-related sclerosing cholangitis
Alcohol, liver and genes: an intricate puzzle
Does the persistently normal aminotransferase levels in hepatitis C still have relevance?
Is recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? Towards a predictive recurrence score
Background. Incidental hepatocellular carcinoma (iHCC) generates uncertainty over risk of recurrence after liver transplantation (LT). Aim. To compare recurrence between iHCC and confirmed HCC diagnosed prior to transpla...